rs7574865 | P value† | |||
G/G* | G/T | T/T | ||
No of patients | 21 | 22 | 9 | |
Women, n (frequency) | 19 (90%) | 20 (91%) | 7 (78%) | 0.54 |
Age, years | 47 (40–59) | 50 (36–66) | 36 (32–45) | 0.10 |
Disease duration, years | 18 (10–31) | 22 (14–31) | 19 (11–26) | 0.56 |
No of ACR criteria | 6 (5–7) | 6 (5–7) | 6 (5–7) | 0.60 |
SLEDAI-2K | 2 (1–4) | 2 (0–4) | 0 (0–3) | 0.23 |
SLICC-DI | 0 (0–2) | 0 (0–1) | 1 (0–3) | 0.51 |
Plasma IFN-α, U/mL | 0 (0–1.5) | 0.4 (0–1.0) | 0 (0–0.9) | 0.74 |
Data are presented as median (IQR) for all parameters except sex, for which the number of women and the frequencies are presented.
*G/G, homozygous protective; G/T, heterozygous; T/T, homozygous risk for rs7574865.
†The χ2 test was used to assess differences in sex distribution and Kruskal-Wallis test was used for the other parameters.
ACR, American College of Rheumatology; IFN-α, interferon alpha; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SLICC-DI, Systemic Lupus International Collaborating Clinics/ACR Damage Index.